Skip to main content
. 2020 Jul 3;10:10960. doi: 10.1038/s41598-020-67883-w

Table 2.

OR with 95% CI of developing MS among subjects categorized by EBNA1 status and smoking.

EBNA-1 IgG Smoking ca/coa OR (95% CI)b OR (95% CI)c AP (95% CI)
Low Never 689/1656 1.0 (reference) 1.0 (reference)
Low Ever 808/1389 1.4 (1.3 to 1.6) 1.5 (1.3 to 1.7)
High Never 2085/1642 3.1 (2.7 to 3.4) 2.7 (2.4 to 3.0)
High Ever 2758/1532 4.4 (3.9 to 4.9) 3.8 (3.4 to 4.3) 0.2 (0.1 to 0.3)
Low Never 689/1656 1.0 (reference) 1.0 (reference)
Low Current 505/814 1.5 (1.3 to 1.7) 1.6 (1.4 to 1.8)
High Never 2085/1642 3.1 (2.7 to 3.4) 2.7 (2.4 to 3.0)
High Current 1820/887 4.9 (4.4 to 5.5) 4.4 (3.9 to 5.0) 0.3 (0.2 to 0.4)
Low Never 689/1656 1.0 (reference) 1.0 (reference)
Low Past 303/575 1.3 (1.1 to 1.5) 1.4 (1.1 to 1.6)
High Never 2085/1642 3.1 (2.7 to 3.4) 2.7 (2.4 to 3.0)
High Past 938/645 3.6 (3.1 to 4.1) 3.1 (2.7 to 3.6) 0.01 (− 0.1–0.1)

AP with 95% CI between high EBNA1 IgG and smoking.

aNumber of exposed cases and controls

bAdjusted for age, sex, residential area, study, and ancestry

cAdjusted for age, sex, residential area, study, ancestry, infectious mononucleosis, adolescent body mass index, DRB1*1501, DRB1*0301, DRB1*1303, DRB1*0801, A*0201, B*4402, B*3801, B*5501, DQA1*0101, DQB1*0302, DQB1*0301, homozygote correction for DRB1*1501, DRB1*0301, and A*0201.